139 dialysis patients: 72 in the Darbepoetin Alfa group and 67 in the short-acting Erythropoietin-Stimulating Agent (ESAs).
- Patients treated with Darbepoetin Alfa showed a statistically significant 1.4% reduction in the incidence of vascular access thrombosis compared to 12% in Epoetin.
- Significantly higher dose change is required in Epoetin vs Darbpoetin Alfa (1.99 vs 1.26, p<0.01).
Darbepoetin Alfa is more effective than traditional ESAs in reducing vascular access thrombosis in dialysis patients.